

Cdc50A (Y-17): sc-242402

BACKGROUND

The eukaryotic cell division cycle consists of a number of gene-controlled sequences that involve cyclin dependent kinases (Cdks) and cell division cycle (Cdc) proteins. Cdc50A (cell cycle control protein 50A), also known as TMEM30A (transmembrane protein 30A) or C6orf67, is a 361 amino acid multi-pass membrane protein that is expressed in placenta, brain and embryonic stem cells and may play a role in cell division. The gene encoding Cdc50A maps to human chromosome 6, which contains 170 million base pairs and comprises nearly 6% of the human genome. Deletion of a portion of the q arm of chromosome 6 is associated with early onset intestinal cancer, suggesting the presence of a cancer susceptibility locus. Additionally, Porphyria cutanea tarda, Parkinson's disease, Stickler syndrome and a susceptibility to bipolar disorder are all associated with genes that map to chromosome 6.

REFERENCES

1. Katoh, Y. and Katoh, M. 2004. Identification and characterization of CDC50A, CDC50B and CDC50C genes in silico. *Oncol. Rep.* 12: 939-943.
2. Vuoristo, M.M., Pappas, J.G., Jansen, V. and Ala-Kokko, L. 2004. A stop codon mutation in COL11A2 induces exon skipping and leads to non-ocular Stickler syndrome. *Am. J. Med. Genet. A* 130: 160-164.
3. McQueen, M.B., Devlin, B., Faraone, S.V., Nimgaonkar, V.L., Sklar, P., Smoller, J.W., Abou Jamra, R., Albus, M., et al. 2005. Combined analysis from eleven linkage studies of bipolar disorder provides strong evidence of susceptibility loci on chromosomes 6q and 8q. *Am. J. Hum. Genet.* 77: 582-595.
4. Batts, K.P. 2007. Iron overload syndromes and the liver. *Mod. Pathol.* 20: S31-S39.
5. Park, E., Kim, S., Kim, S.J., Park, Y., Lee, J.S., Yoo, J.C., Kim, C.S., Kim do, K., Lee, S.Y., Chun, H.S. 2007. Modulation of Parkin gene expression in noradrenergic neuronal cells. *Int. J. Dev. Neurosci.* 25: 491-497.
6. Safadi, S.S. and Shaw, G.S. 2007. A disease state mutation unfolds the Parkin ubiquitin-like domain. *Biochemistry* 46: 14162-14169.
7. Online Mendelian Inheritance in Man, OMIM[™]. 2007. Johns Hopkins University, Baltimore, MD. MIM Number: 611028. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>
8. Bläker, H., Mechttersheimer, G., Sutter, C., Hertkorn, C., Kern, M.A., Rieker, R.J., Penzel, R., Schirmacher, P. and Kloor, M. 2008. Recurrent deletions at 6q in early age of onset non-HNPCC- and non-FAP-associated intestinal carcinomas. Evidence for a novel cancer susceptibility locus at 6q14-q22. *Genes Chromosomes Cancer* 47: 159-164.
9. Paulusma, C.C., Folmer, D.E., Ho-Mok, K.S., de Waart, D.R., Hilarius, P.M., Verhoeven, A.J. and Oude Elferink, R.P. 2008. ATP8B1 requires an accessory protein for endoplasmic reticulum exit and plasma membrane lipid flippase activity. *Hepatology* 47: 268-278.

CHROMOSOMAL LOCATION

Genetic locus: TMEM30A (human) mapping to 6q14.1; Tmem30a (mouse) mapping to 9 E1.

SOURCE

Cdc50A (Y-17) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of Cdc50A of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-242402 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

Cdc50A (Y-17) is recommended for detection of Cdc50A of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with Cdc50B or Cdc50C.

Cdc50A (Y-17) is also recommended for detection of Cdc50A in additional species, including equine, canine and bovine.

Suitable for use as control antibody for Cdc50A siRNA (h): sc-95079, Cdc50A siRNA (m): sc-142215, Cdc50A shRNA Plasmid (h): sc-95079-SH, Cdc50A shRNA Plasmid (m): sc-142215-SH, Cdc50A shRNA (h) Lentiviral Particles: sc-95079-V and Cdc50A shRNA (m) Lentiviral Particles: sc-142215-V.

Molecular Weight of Cdc50A: 41 kDa.

Positive Controls: Hep G2 cell lysate: sc-2227.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker[™] compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker[™] Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz[™] Mounting Medium: sc-24941.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.